News Merida raises $121m for Graves drug, and other financings Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics.
News Lilly soars on first data for oral obesity candidate Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.
News Spruce Bio sows the seeds of its new future Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.
News UK Biobank responds to fears over Chinese access to NHS data Access to de-identified NHS patient data by researchers based in China is not a security concern, according to UK Biobank.
News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Ironwood crashes down as FDA seeks new phase 3 trial Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
